vTv Therapeutics (NASDAQ:VTVT) Raised to “Hold” at Wall Street Zen

vTv Therapeutics (NASDAQ:VTVT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Other research analysts also recently issued reports about the company. Weiss Ratings downgraded vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. HC Wainwright dropped their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Rodman & Renshaw assumed coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 target price for the company. Finally, BTIG Research raised their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, vTv Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $55.83.

vTv Therapeutics Price Performance

Shares of NASDAQ:VTVT opened at $30.57 on Friday. The company’s 50-day moving average price is $32.14 and its two-hundred day moving average price is $33.87. vTv Therapeutics has a one year low of $19.50 and a one year high of $44.00. The stock has a market capitalization of $120.45 million, a PE ratio of -28.84 and a beta of 0.21.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, analysts anticipate that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for metabolic and inflammatory diseases. The company’s research programs are based on its proprietary drug-discovery platform and are intended to address conditions for which additional treatment options are needed.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being studied as an adjunct to insulin for people with type 1 diabetes.